Tag:
Bayer
Latest Headlines
Latest Headlines
OncoMed offers $115M IPO bet on cancer stem cell work
A year after scoring a $20 million milestone from Bayer, OncoMed Pharmaceuticals is preparing to see if it can generate enough excitement from investors for its cancer stem cell work to support a $115 million IPO.
Indian gov't probes drug regulator after scathing review
Days after a parliamentary report noted shoddy oversight of approvals, the Indian government has mounted an investigation into the alleged misdeeds. Meanwhile, big names in biopharma have surfaced in the sea of allegations.
Report: Bayer contemplates sale of blood glucose meter business
This just in: Bayer is reportedly talking with potential buyers of its blood glucose meters business.
Bayer slams Indian government, Cipla on Nexavar copies
Since the Indian government yanked its exclusivity on the cancer drug, the German company is fighting back.
India's Cipla puts fire-sale prices on cancer drugs
Indian genericsmaker Cipla will sell its copies of cancer drugs for a fraction of their branded counterparts.
Interested shoppers prompt Warner to weigh sale options
Warner Chilcott is the latest drugmaker to stir up the M&A pot. The company is looking at its options, including a possible sale, Bloomberg reports.
Rumors put Bayer, Onyx at the M&A altar
With the Watson Pharmaceuticals-Actavis deal wrapped up, M&A hounds need something new to sniff out. And voilá!
Buzz: Is Bayer looking to buy Onyx Pharma?
Reuters reported today that Bayer is looking to close a multibillion-euro acquisition deal, quoting sources who say that an announcement could be "imminent."
Piramal lays claim to a late-stage imaging rival for Lilly's Alzheimer's agent
Piramal wasn't saying just how much it paid for the portfolio, but rather breezily claimed that the market for such Alzheimer's imaging agents could amount to $1.5 billion.
Bloomberg: Bayer to pay $110 million to get out from under 500 Yaz lawsuits
Three months of negotiations have apparently resulted in Bayer deciding that claims against its Yasmin line of birth control are worth about $220,000 each.
